OYST News and Press, Oyster Point Pharma Inc. From 07/31/20

PRINCETON, N.J., July 31, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced th...

Developing novel drugs for unmet medical needs remains the mission for many emerging drug developers. These pharma companies tackle a range of diseases but have one common attribute. Healthcare investors can look past the development risk. Two companies have approved drugs recently launched in...

PRINCETON, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the closing of a p...

Cassava Sciences (NASDAQ: SAVA )  -82%  after Alzheimer's candidate flunks mid-stage study. More news on: Cassava Sciences, Inc., Synthesis Energy Systems, Inc., Creative Realities, Inc., Stocks on the move, , Read more ...

Oyster Point Pharma (NASDAQ: OYST ) has priced its public offering of 3.75M common shares at $28.00/share, for expected gross proceeds of $105M. More news on: Oyster Point Pharma, Inc., Healthcare stocks news, Read more ...

PRINCETON, N.J., May 15, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the pricing of its...

PRINCETON, N.J., May 12, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it has commen...

Protalix Reports Positive Topline Results for Phase III Data Protalix BioTherapeutics Inc. ( PLX ) announced positive topline data from Phase III BRIDGE clinical trial of its lead drug candidate PRX-102. This Phase III study was an open label, single arm switch-over 12 month long study a...

Image source: The Motley Fool. Oyster Point Pharma, Inc.   (NASDAQ: OYST) Q1 2020 Earnings Call May 11, 2020 , 8:00 a.m. ET Operator Continue reading

Oyster Point Pharma Inc (OYST) Q1 2020 Earnings Conference Call May 11, 2020 8:00 AM ET Company Participants Daniel Lochner – Chief Financial Officer Jeffrey Nau – President and Chief Executive Officer John Snisarenko – Chief Commercial Officer Conference ...